Author: Ryan Allway

TORONTO, April 30, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI)(FRANKFURT:75M)(OTCQB:MRRCF)(“Maricann” or the “Company”), is pleased to announce that the Company is now part of an exclusive group of Canadian Licensed Producers to be Good Manufacturing Practice (GMP) certified in accordance with the European Medicines Agency’s GMP standards.

GMP standards are regarded as the highest assurance of quality and safety a pharmaceutical manufacturer can receive. It is a rigorous process that Maricann initiated in Q4 of 2017 when German health inspectors visited its current Langton, Ontario facility for a thorough review of the operations. With today’s announcement, Maricann becomes only the 6^th Canadian producer of medical cannabis to be awarded this distinction.

“EMA-GMP certification of our cultivation facility in Canada demonstrates further progress at Maricann.  External validation of our operations provides comfort to our patients and consumers that we exceed industry standards.  Our commitment to total quality, from origination to finished product is now certified,” stated Ben Ward, CEO.

This certification allows the Company to export dried cannabis flower into the rapidly growing medical cannabis markets of the EU. While governments decide how to license and regulate production within their own jurisdictions on European soil, companies with the ability to export are at a distinct advantage to capitalize in these markets where a significant shortage of product exists.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out to support existing and future patient growth.

Forward Looking Information
Certain statements in this document, including, without limitation, statements with respect to our future positioning in the European cannabis market, the future designed production capacity of Maricann’ expanded facility and other subjects, contain forward-looking statements which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to its operations, expansion project and other future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. In the case of the Company’s expected designed production capacity for its expansion project facility, the expectations of management are based on the production results of its current facility adjusted to reflect the greater square footage of the expanded facility and on the designs and plans of the new facility and assumes it will be successfully completed, and operate as planned.  Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; failure to obtain all necessary regulatory approvals; risks inherent to building and bringing into production new facilities;  uncertainties with respect to estimated production capacity based on designs and plans; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition and other risks identified in the Company’s latest annual information form and other disclosure documents filed under its profile at www.sedar.com. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Maricann, please visit our website at www.maricann.com

CONTACT INFORMATION

Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665

Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland

 

Source: GlobeNewswire (April 30, 2018 – 12:15 AM EDT)

Source: PR Newswire (April 25, 2018 – 8:00 AM EDT)

VANCOUVER, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSX-V:NSP) (OTCQB:NSPDF) (Frankfurt:50N) is pleased to announce the acquisition of Absorbent Concepts Inc.(“ACI”), an organic hemp processor located in Abbotsford, B.C.

Naturally Splendid CEO Mr. Douglas Mason states, “The acquisition of ACI represents a major milestone for NSE creating a critical link in becoming a truly vertically integrated, industrial hemp biotech and consumer products company. In addition to capturing more value chain margin with our existing industrial hemp lines, the addition of the expertise within ACI strengthens our Dealer License application and provides significant resources as we continue on the path to add a cannabinoid extraction facility.”

As stated in a previous news release dated February 6^th, 2018, the regulatory purpose for a Dealer License is to enable legal possession of regulated substances such as cannabidiol (CBD) for the purposes of formulating, manufacturing, distributing and import/export.

Absorbent Concepts Inc. (doing business as ACI Foods) is a science-based, industrial hemp seed processing business located in Abbotsford, BC. Listed as the only strictly organic hemp seed processor in North America, ACI is a significant producer of hulled seed, hemp seed oil and high percentage protein powder, among a long list of in-development nutritional products and processes. Although ACI has specialized in processing organic hemp products, operations will be expanded to accommodate the ability to provide a full range of conventional hemp products.

In business since November 2013, ACI was conceived by Pete Scales, an entrepreneur, inventor/R&D specialist, applied scientist, lecturer and long time believer in the power and many gifts of hemp, including full plant utilization, which in turn includes cannabinoid extraction. In addition to a wealth of hemp processing knowledge and experience, the ACI team brings to NSE a substantial body of technical expertise in cannabinoid extraction, nutritional product development, laboratory analysis, as well as long-standing contractual relationships with farmers. These relationships will be leveraged to forge secure supply agreements for organic and conventional industrial hemp for the traditional seed harvest, and also for new opportunities in the CBD cultivation pursuant to the anticipated Cannabis Act being revised by the Canadian Federal Government later this year. In fiscal 2017, ACI recorded total revenues of $1,080,869 (unaudited) and a loss of $119,714 (unaudited). In ACI’s first quarter, total revenues were $156,670 (unaudited) which resulted in a loss of $114,644 (unaudited).

According to an article published by Hempster on April 16^th, 2018, “Hemp is a much richer source of CBD than marijuana, and it makes economic sense to extract CBD from this abundant crop. Currently, Canadian farmers are forced to destroy the leaves and flowers of their hemp plants. But this will all change when the Cannabis Act comes into effect, likely in the late summer or fall of 2018. Once enacted, hemp farmers will be able to sell their crops to licensed producers for CBD extraction.”

Canadian Hemp Trade Alliance President and Naturally Splendid Director Russell Crawford states, “As holders of a Dealers License, Naturally Splendid will be positioned to leverage the upcoming whole plant utilization regulations. ACI’s relationship with farmers is a great catalyst in securing acreage for CBD production.”

The acquisition of ACI by Naturally Splendid is pursuant to the terms of the share purchase agreement among ACI, Pete Scales and Naturally Splendid. Naturally Splendid acquired all of the issued and outstanding shares of ACI in consideration of repaying and/or assuming certain bank loans of ACI that total $640,018.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp and non-psychoactive cannabinoid compounds in a broad spectrum of applications.

Naturally Splendid currently has four innovative divisions:

    (1)    BIOTECHNOLOGY –  Focused on three major platforms:

                        (1)   Proprietary HempOmega™ encapsulation

(2)   Extraction and formulation with Cannabidiol (CBD)

(3)   Hemp and plant-based proteins.

     (2) CONSUMER PRODUCTS –

· NATERA® – brand of retail hemp and superfood products distributed throughout North America, Asia and Europe.

· Prosnack Natural Foods Inc. (Elevate Me™) – lifestyle brand of healthy meal replacement products distributed throughout North America.

· Chi Hemp Industries Incorporated (CHII) – e-commerce platform for natural and organic hemp products.

· PawsitiveFX® – topical pet care products.

· NATERA®CBD – retail hemp-based cannabinoid nutraceutical and cosmeceutical products distributed in Asia.

· NATERA®Skincare – brand of retail hemp based cosmeceutical products.

     (3) NATERA® Ingredients – bulk ingredients including HempOmega™.

(4) Co-Packaging/Toll-Processing – packaging for house-brands (NATERA® and CHII) and third-party partners.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573.

On Behalf of the Board of Directors

Mr. Douglas Mason
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office:  (604) 465-0548
Fax:      (604) 465-1128

E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: GlobeNewswire (April 25, 2018 – 7:00 AM EDT)

Toronto, Ontario–(Newsfile Corp. – April 24, 2018) – RISE Life Science Corp. (CSE: RLSC) (formerly Luminor Medical Technologies Inc.) (the “Company” and/or “RISE”) today announced that it has commissioned a longitudinal study to investigate sexual function and health concerns, and, how cannabis products designed for sexual enhancement and health affect sexual behaviors and performance. The RISE Report on Cannabis and Sexual Health and Wellness (the “RISE Study”) will be significant in its long-term open-ended focus, overall scope, and the value of the data it is designed to capture.

Dr. Regina Nelson, a behavioral scientist and one of America’s leading cannabis educators, will lead the study. Dr. Nelson is supported in these efforts by Dr. Christopher J. Smith, a social science expert, and Dr. Jon Ross, a healthcare and public policy expert.

“As cannabis evolves into widespread medical and mainstream commercial use, the benefits of cannabis products and their relation to sexual health are particularly important to every stakeholder, from public health officials to companies making cannabis-based products, and especially for the general consumer.” commented Dr. Nelson, study designer and principal researcher.

“To date, no scholarly investigation of the physiological connection between cannabis and sexual health has ever been undertaken at this scale. This study presents the opportunity to expand our collective knowledge, increase our understanding, and create a critically important data set regarding sexual behaviour, health, and wellness.”

“We are investing in this study because it is central to the ongoing development of consumer products that individuals and couples believe in and actually want to use,” said Anton Mattadeen CEO of RISE Life Science. “The proprietary data generated by this study will not only add necessary information to the subject of sexual health, it will also inform RISE of the best possible product development decisions to meet the needs of our customers, provide us with a competitive advantage in the marketplace, and help us remain right in the middle of this important conversation with our expanding consumer community.”

The Study — Key Facts:

• Clear Purpose: This is a long-term observational study collecting quantitative and qualitative data, exploring cannabis usage as an aid for sexual performance and collection of experiential data related to the use of RISE sexual health and wellness products;
• No Gender Bias: We will look at specific differences in effect across genders, as our study will extend beyond heterosexual participants;
• Real User Experiences: In addition to clinical and statistical data, the RISE Study will collect consumer stories and experiences;
• Important Observations: The study will focus on many critical areas in need of review:

o    Emotional and physical satisfaction with and without a partnered sexual relationship;
o    Satisfaction with sexual health and function;
o    The importance of sex, sexual function and health to quality-of-life; and
o    How introducing novel cannabis products designed for sexual enhancement and health affect sexual experiences.

• Usage Mode Profiles: Research will range beyond smoking and vaping and include other important forms of consumption such as oral sprays, oils, concentrates, edibles and topical solutions.
• Anonymity and Security: Given the topic and increasing privacy concerns, we are protecting personally identifiable information by simply not collecting it at all. This is a strictly anonymous study, with rich profile data and outcomes directly related to cannabis product use.

The study is expected to initially enroll approximately 200 participants during its beta test phase starting in the spring of 2018, with the official study launch tentatively scheduled for September of 2018. As the study continues to expand over time, the long-term goal is to engage with thousands of participants.

About Dr. Regina Nelson

Regina Nelson is a published author of several books, and earned her Ph.D. in Ethical and Creative Leadership at Union Institute and University. Her doctoral studies concentrate on the issue of medical cannabis. In 2012, Dr. Nelson published her first peer-reviewed article, Framing Integral Leadership within the Medical Cannabis Community. She has gone on to publish and present in twenty peer-reviewed forums, including events hosted by the International Leadership Association, the International Cannabinoid Research Society, and the Integral European Conference. In addition to her role as CEO of Integral Education and Consulting, LLC, she is also a founding officer of the eCS Therapy Center, an Integral 501C3 organization building awareness of the endocannabinoid system (eCS) and championing community-based education via the Plant a Seed for Cannabis Education Tour.

About RISE Life Science Corp.

RISE Life Science Corp. develops cutting-edge cannabis consumer products for both medical and adult-use markets around the world in jurisdictions that have legal regulatory frameworks in place. All products are based on patent-pending formulations and processes to produce specifically targeted effects. A key area of focus for RISE is research-based formulations to address adult sexual health and wellness for both women and men.

For further information:
For more information, please contact:
Mark Komonoski
Communication Director
mark@komonoski.com
877-255-8483
403-470-8384

Or:

Anton Mattadeen
President & CEO
anton@riselifescience.com
416-899-9462

The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in RISE‘S periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward- looking statements. Forward-looking statements may include, without limitation, statements including the Company’s expectations with respect to pursuing new opportunities and its future growth and other statements of fact.

Although RISE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal Laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. RISE disclaims any intention or obligation to update or revise such information, except as required by applicable law, and RISE does not assume any liability for disclosure relating to any other company mentioned herein.

Source: Newsfile Corp. (April 24, 2018 – 8:55 AM EDT)

Gary Symons, Director of Communications, communications@delta9.ca, 250.300.9352Copyright CNW Group 2018

Source: Canada Newswire (April 24, 2018 – 5:30 AM EDT)

TORONTO, April 23, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI)(FRANKFURT:75M)(OTCQB:MRRCF)(“Maricann” or the “Company”), is pleased to announce that it has received all of the necessary approvals from Health Canada to commence cultivation in Phase One of the Company’s new, state-of-the-art grow facility in Langton, Ontario, Canada. This is Maricann’s third licence issued by Health Canada.

“The licensing of Phase One of our Canadian expansion is a major milestone for both our employees and shareholders. This facility could be built in the Arctic, or the equator and still replicate the exact same cannabis every time. Due to the control and automation platform, combined with a unique building envelope design from standard stock, pre-engineered steel and greenhouse components, our overall costs are reduced,” stated Ben Ward, CEO

The design of the facility is revolutionary, combining the best of indoor cultivation and greenhouse technology. We utilize natural sunlight in a completely controlled, sealed, and energy efficient cultivation environment. Our automated process allows us to reduce ongoing operational costs to create a meaningful cost advantage.

Ward continued: “Environment and genetics are the two most critical elements in the production of cannabis. Our new facility, combined with Rare Dankness Cannabis Cup award winning genetics, provides Maricann with the ability to supply a superior product to the market. We invested significantly in a new purpose-built facility, with an optimal work flow that complies with GMP production standards and Six Sigma operations. This will result in ongoing low cost production of a premium quality product. We plan to bring our experience and expertise with us globally in replication of this world leading facility, designed by our VP of Infrastructure, Jeff Ayotte.”

Elements of the expansion include:

• Segmentation of cultivation rooms into 8,800 square feet, to create an optimal environment for each strain’s cultivation that can be individually controlled, mitigating risk in potential cross contamination with individual pressurization in each room;
• 1,550,000 litre cistern, recycling all water used in the facility through a seven layer organic biological pond, reducing waste water to less than 10,000 litres per year.
• R-38 Exterior building envelope
• Natural Gas co-generation electric facility to produce low cost electricity.
• Co2 scrubber, using the exhaust of the natural gas co-gen facility and boilers, cleaning and then using as a fertilizer for plants in the increase of Co2 in each cultivation room, instead of industry standard liquid Co2.
• Diffused glass roof, combined with supplemental LED lights to provide natural sunlight, and enhanced lumen penetration of the canopy.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, with a designed expected capacity of producing 95,000 kg (based on conservative estimates) of dry cannabis flower per year to support existing and future patient growth.

Forward Looking Information
Certain statements in this document, including, without limitation, statements with respect to the future designed production capacity of Maricann’s expanded facility and other subjects, contain forward-looking statements which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to its operations, expansion project and other future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. In the case of the Company’s expected designed production capacity for its expansion project facility, the expectations of management are based on the production results of its current facility adjusted to reflect the greater square footage of the expanded facility and on the designs and plans of the new facility and assumes it will be successfully completed, and operate as planned.  Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; failure to obtain all necessary regulatory approvals; risks inherent to building and bringing into production new facilities;  uncertainties with respect to estimated production capacity based on designs and plans; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition and other risks identified in the Company’s latest annual information form and other disclosure documents filed under its profile at www.sedar.com. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Maricann, please visit our website at www.maricann.com

CONTACT INFORMATION

Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665

Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland

Source: GlobeNewswire (April 23, 2018 – 12:15 AM EDT)

Speakeasy Cannabis Club Ltd., www.speakeasygrowers.com, Telephone: 604-283-1722Copyright CNW Group 2018

Source: Canada Newswire (April 19, 2018 – 4:05 PM EDT)

Toronto, Ontario–(Newsfile Corp. – April 19, 2018) – RISE Life Science Corp. (CSE: RLSC) (formerly Luminor Medical Technologies Inc. (the “Company” or “RISE”) is pleased to announce that, further to it press release dated March 29, 2018, it has closed tranches (each a “Tranche”) of its previously announced non-brokered private placement (the “Offering”) through the issuance of an aggregate of 7,366,166 units (each a “Unit”) at a price of $0.30 per Unit for gross proceeds of $2,209,849.80. Each Unit is comprised of one common share (“Common Share”) of the Company and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share for a period of twenty-four (24) months from the date of closing of the Tranche at a price of $0.45 per Common Share. The proceeds of the Offering will be used for general working capital purposes. The Company may be closing additional tranches of the Offering until May 11, 2018.

Anton Mattadeen, CEO and a RISE founder comments on the progress: “This first raise as RISE represents another step in a carefully constructed plan to enable the launch of our California operations in June. We are right on track to introduce our initial suite of sexual health and wellness products to the largest, and one of the most sophisticated cannabis consumer markets in the world. The time and effort we have spent in California will inform how RISE commercializes our sexual health and wellness formulations in other legalized jurisdictions around the globe.”

Further news on our brand and specific product line up will be disclosed on or before 5/20, and then our official California product launch on 6/20, so May 20th and June 20th respectively.”

Certain eligible persons (“Finders”) were paid a commission equal to 8% of the gross proceeds raised from subscribers introduced to the Company by such Finders and issued non-transferable broker warrants (“Broker Warrants”) equal to 8% of the Units issued pursuant to the Offering. Each Broker Warrant entitles the holder thereof to purchase one Common Share for a period of twenty-four (24) months from the date of closing of the Offering at a price of $0.30 per Common Share.

A portion of the Offering was completed pursuant to Multilateral CSA Notice 45-318 — Prospectus Exemption for Certain Distributions through an Investment Dealer (“CSA 45-318”) and the corresponding blanket orders and rule implementing CSA 45- 318 in the participating jurisdictions in respect thereof (collectively with CSA 45-318, the “Investment Dealer Exemption”). As at the date hereof, the Investment Dealer Exemption is available in each of British Columbia, Alberta, Saskatchewan, Manitoba and New Brunswick.  Pursuant to CSA 45-318, each subscriber relying on the Investment Dealer Exemption must obtain advice regarding the suitability of the investment from a registered investment dealer. In accordance with the requirements of CSA 45-318, there is no material fact or material change of the Company that has not been disclosed.

In addition to conducting the Offering pursuant to the Investment Dealer Exemption, the Offering was also conducted pursuant to other available prospectus exemptions.

The Offering constituted a related party transaction within the meaning of Multilateral Instrument 61-101 (“MI 61-101”) as an insider of the Company subscribed for an aggregate of 33,333 Units pursuant to the Offering. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as the fair market value of the participation in the Offering by the insider does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the Offering, which the Company deems reasonable in the circumstances in order to complete the Offering in an expeditious manner.

The Company has also issued an aggregate of 83,333 common shares in settlement of an aggregate of $30,307 of indebtedness with a vendor at a price of $0.30 per common share.

This press release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States and may not be offered or sold within the United States (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About RISE Life Science Corp.

RISE Life Science Corp. develops cutting-edge cannabis consumer products for both medical and adult-use markets around the world in jurisdictions that have legal regulatory frameworks in place. All products are based on patent-pending formulations and processes to produce specifically targeted effects. A key area of focus for RISE is evidence-based formulations to address adult sexual health and wellness for both women and men.

For more information, please contact:

Mark Komonoski
Communication Director
mark@komonoski.com
877-255-8483
403-470-8384

Or:

Anton Mattadeen
President & CEO
anton@riselifescience.com
416-899-9462

The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for the adequacy or accuracy of this news release.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Luminor’s (now RISE) periodic filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward- looking statements. Forward-looking statements may include, without limitation, statements including the Company’s expectations with respect to pursuing new opportunities and its future growth and other statements of fact.

Although RISE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US Federal Laws; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. RISE disclaims any intention or obligation to update or revise such information, except as required by applicable law, and RISE does not assume any liability for disclosure relating to any other company mentioned herein.

Source: Newsfile Corp. (April 19, 2018 – 2:04 PM EDT)

Choom Holdings Inc.: Chris Bogart, President & CEO, T: 604.683.2509, F: 604.683.2506, E: chris@choom.ca; Alex Porporo, Investor Relations, T: 604.683.2509, F: 604.683.2506, E: alex@choom.ca; Chris Gagan, SVP Branding, Marketing, T: 604.683.2509, F: 604.683.2506, E: chrisg@choom.caCopyright CNW Group 2018

Source: Canada Newswire (April 19, 2018 – 8:00 AM EDT)

Gary Symons, Director of Communications, Delta 9 Cannabis Inc., communications@delta9.ca, 250.300.9352Copyright CNW Group 2018

Source: Canada Newswire (April 19, 2018 – 5:30 AM EDT)

Vancouver, British Columbia–(Newsfile Corp. – April 18, 2018) – Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the “Company” or “Abattis“) is pleased to announce that it has entered into a share purchase agreement to acquire (the “Acquisition“) the remaining 10% ownership interest in its subsidiary, Gabriola Green Farms Inc. (“Gabriola“).

“We are very happy to now own a 100% interest in Gabriola and integrate it as a wholly-owned subsidiary of Abattis. We believe that Gabriola’s anticipated LP will complete our suite of downstream offerings and be the highlight of our growth into a full service cannabis company,” stated Rob Abenante, Abattis President and CEO.

Abattis will acquire the remaining 10% ownership interest in Gabriola from CannaNUMUS Blockchain Inc. for $2.5 million. Following completion of the Acquisition, Gabriola will be a wholly-owned subsidiary of the Company.

Gabriola is a British Columbia company that has applied for a license to produce under the Access to Cannabis for Medical Purposes Regulations (“ACMPR“) on Gabriola Island, one of the gulf islands located in the Strait of Georgia off the coast of British Columbia. Gabriola Island has a consistent temperature and humidity level, which makes it well suited to greenhouse growing.

Gabriola’s production facilities are expected to be constructed in two phases:

• Phase 1 – Buildout of its 6,000-square-foot state-of-the-art facility, consistent with ACMPR standards.
• Phase 2 – Upon completion of the Phase 1 buildout, Gabriola will build out an expansion of approximately 20,000 square feet.

About Abattis Bioceuticals Corp.

Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.

ON BEHALF OF THE BOARD OF
ABATTIS BIOCEUTICALS CORP.,

“Rob Abenante”
Robert Abenante, President & CEO

For more information, please visit the Company’s website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “intends”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this press release include statements regarding: the Acquisition and the expected completion thereof; Gabriola’s LP application and the expected effect the LP, once received, will have on Abattis’s business profile and offerings; Gabriola’s plans for an approximately 26,000 square foot production facility, including respecting the two expected phases of such buildout. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties, including: that the Acquisition will not complete; that Gabriola’s application for an LP will be unsuccessful; that, once received, the effect of Gabriola’s LP on Abattis’s business profile and offerings will not be as expected; that Gabriola’s construction plans will not come to fruition or will not be carried out as expected; that the Company will not be able to execute its proposed business plan in the time required or at all due to regulatory, financial or other issues; that the Company’s competitors may develop competing technologies; changes in regulatory requirements; and other factors beyond the Company’s control. Additional risk factors are included in the Company’s Management’s Discussion and Analysis, available under the Company’s profile on www.sedar.com. The forward-looking statements are made as at the date hereof and the Company disclaims any intent or obligation to publicly update any forward-looking statements, where because of new information, future events or results, or otherwise, except as required by applicable securities laws.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Source: Newsfile Corp. (April 18, 2018 – 1:22 PM EDT)

please contact: 8 Wellington St. E. Mezzanine Level | Toronto, On | M5E 1C5 | www.HighHampton.com; David E. Argudo, Chief Executive Officer, Email: david@highhampton.com Or Christian Scovenna, Director & VP Corporate Finance, Email: christian@HighHampton.com, Phone: 1.844.420.CaliCopyright CNW Group 2018

Source: Canada Newswire (April 18, 2018 – 3:15 AM EDT)

TORONTO, April 18, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI)(FRANKFURT:75M)(OTCQB:MRRCF) (“Maricann” or the “Company”), is pleased to announce that the first seeds will be planted today on its contract farmed 164 hectares (~405 acre) of agricultural land in Saxony, Germany, through Mariplant GmbH a 95% owned subsidiary of the Company focused on nutraceutical non-THC cannabis. The cultivation site is less than 30 minutes drive from the Company’s Ebersbach Campus, near Dresden, Germany.

The Ebersbach facility is currently under retrofit of 8,000 sq. m (86,111 sq. ft) separated from its Maricann GmbH operations, to accommodate drying equipment capable of processing 1,000 kg of wet cannabis per hour. Storage and extraction equipment from Advanced Extraction Systems (AES) will be utilized to process up to 200 kg of cannabis flowers per day.¹

Mariplant’s operation will focus on producing isolates of CBD and CBG, which are considered to be the most desirable cannabinoids. Maricann will add terpenoids and flavonoids in addition to its VesiSorb emulsion technology to create Mariplant products for distribution as food supplements across Germany and the greater European Union. Terpenoids and Flavonoids from Maricann’s Haxxon cultivation and extraction operation from feminized cannabis will be added to improve efficacy.

Ben Ward, CEO of Maricann stated, “We believe that this large scale outdoor cannabis cultivation and extraction operation has the potential to reduce our costs of production significantly, specifically for isolate CBD, CBN and CBG.  Through this initiative, we expect to be able to produce our own active ingredients for our products, reducing material costs of active ingredients for Mariplant products that we currently purchase from third parties. Our expectation is that this will result in a further competitive advantage for Mariplant, benefiting in a differentiated product through VesiSorb’s patented delivery technology, with the end result of value creation for Maricann shareholders”.

Mariplant is a standalone company in Germany registered for agriculture, with its General Manager Josef Spaeth who has the designation of registered farmer (Landwirt).

Mariplant will sell finished product VesiSorb gel capsules into the German market through its online shop www.mariplant.de.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario, Canada where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada, and Dresden, Saxony, Germany. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) build out, with a designed expected capacity of producing 95,000 kg (based on conservative estimates) of dry cannabis flower per year to support existing and future patient growth.

Forward Looking Information

Certain statements in this document, including, without limitation, statements with respect to its future activities, targeted or expected future production, expected production cost reductions and other subjects, contain forward-looking statements which can be identified by the use of forward-looking terminology such as “believes”, “expects”, “may”, “desires”, “will”, “should”, “projects”, “estimates”, “contemplates”, “anticipates”, “intends”, or any negative such as “does not believe” or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to its operations, and other future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. In the case of the Company’s expected designed production capacity for its expansion project facility, the expectations of management are based on the designs and plans of the new facility and assumes it will be successfully completed, licensed and operate as planned. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management’s control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; failure to obtain all necessary regulatory approvals; risks inherent to building and bringing into production new facilities;  uncertainties with respect to estimated production capacity based on designs and plans; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition and other risks identified in the Company’s latest annual information form and other disclosure documents filed under its profile at www.sedar.com. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking information.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Maricann, please visit our website at www.maricann.com

CONTACT INFORMATION

Investor Relations
Graham Farrell
Director of Investor Relations
graham@maricann.com
647-643-7665

Corporate Headquarters (Canada)
Maricann Group Inc. (Toronto)
845 Harrington Court, Unit 3
Burlington Ontario L7N 3P3
Canada
289-288-6274

European Headquarters (Germany)
Maricann GmbH
Thierschstrasse 3, 80538 Munchen, Deutschland

___________________________________

¹ Conservative estimates based on manufacturer’s design

Source: GlobeNewswire (April 18, 2018 – 9:23 AM EDT)